Therefore, we investigated the relationship between SGO1 expression and four tumor heterogeneity indicators across pan-cancer, including tumor mutation burden (TMB), mutant allele tumor heterogeneity (MATH), microsatellite instability (MSI), purity, homologous recombination deficiency (HRD), loss of heterozygosity (LOH), and ploidy, to determine whether SGO1 can predict the response to immunotherapy. Here, SGO1 is linked to neoplasm.